In December 2025, the NPPA announced a revision of the ceiling prices for several cardiovascular drugs; however, Verapamil remained unaffected, allowing manufacturers to maintain their pricing strategies.
In January 2026, the EMA initiated a review of calcium channel blockers, including Verapamil, to assess their safety profiles in light of new clinical data. This ongoing evaluation may lead to updated guidelines and necessitate adjustments in product information.
In February 2026, the FDA updated its Import Alert 66-66 to include additional scrutiny on API labeling compliance, emphasizing the need for exporters to ensure accurate and complete labeling to prevent import detentions.
In March 2026, the WHO published the 22nd edition of its Model List of Essential Medicines, reaffirming the inclusion of Verapamil and highlighting its continued importance in global health initiatives.
In March 2026, the CDSCO issued a directive requiring all Verapamil manufacturers to submit updated stability data to ensure ongoing compliance with quality standards, reflecting the agency's commitment to maintaining the integrity of pharmaceutical products.
These developments underscore the dynamic regulatory environment surrounding Verapamil, necessitating vigilant compliance and proactive engagement by exporters to navigate the evolving landscape effectively.
